Product
MTBVAC
5 clinical trials
2 indications
Indication
TuberculosisIndication
HIV infectionClinical trial
Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic RegionStatus: Completed, Estimated PCD: 2022-05-19
Clinical trial
Randomised, Double-Blind, Controlled Phase 3 Trial to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Healthy HIV Unexposed (HU) and HIV Exposed Uninfected (HEU) Newborns in Tuberculosis-Endemic Regions of Sub-Saharan AfricaStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 2b, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine, MTBVAC, Against TB Disease in Interferon Gamma Release Assay Positive Adolescents and Adults Aged 14-45 Years, Living in a TB Endemic Region.Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South AfricaStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled,Safety, Immunogenicity, and Dose-escalation Study in Adults With and Without Latent Tuberculosis Infection in South AfricaStatus: Completed, Estimated PCD: 2021-09-05